Dyadic International Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Dyadic International, Inc. on April 6, 2006, reporting events that occurred on April 4, 2006. The filing addresses the entry into a material definitive agreement regarding executive compensation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to the terms of stock option grants:
- Exercise Price: $4.40 per share (based on the closing price on the American Stock Exchange on April 4, 2006).
- Total Options Granted: 110,000 options distributed among four named executive officers.
Material Changes
The primary material change is the approval by the Compensation Committee of stock option awards for services rendered in 2005. The grants were made under the Dyadic International, Inc. 2001 Equity Compensation Plan to the following executives:
- Wayne Moor (CFO): 30,000 options
- Kent Sproat (EVP, Enzyme Business): 30,000 options
- Ratnesh (Ray) Chandra (SVP, Marketing): 30,000 options
- Alexander (Sasha) Bondar (VP, Strategy): 20,000 options
These options vest at a rate of 25% per year over four consecutive twelve-month periods and have a ten-year term.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. The document is strictly a disclosure of the executive compensation agreement.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2001 Equity Compensation Plan to assess remaining capacity.
- Confirm the current market price of Dyadic International stock relative to the $4.60 exercise price to evaluate the intrinsic value of the grants.
- Review the vesting schedule to understand the retention timeline for key executives.
- Check subsequent filings for any changes to the Equity Compensation Plan referenced in this report.